The Federal Trade Commission filed a lawsuit to prevent Edward LifeSciences from acquiring JenaValve Technology, arguing the deal would stifle innovation in treatments for aortic regurgitation, a serious heart condition in which blood leaks in the heart chamber, Bloomberg reported Aug. 6.
The complaint, filed in U.S. District Court for the District of Columbia, alleges the merger would reduce competition in a market where few treatment options exist.
JenaValve’s device has received approval for use in the European Union and is expected to be cleared by the FDA later in 2025, the report said. Despite the lawsuit, Edward LifeSciences said it intends to pursue the acquisition, arguing the deal would help the devicemakers’ innovation footprint and improve access to treatments.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
